Status: Closed
Activation Date: 2006AUG22
Closing Date: 2011APR04
Phase: I
Description: A Phase I Study Of AT7519M Given Twice Weekly In Patients With Advanced Incurable Malignancy
Eligibility: Advanced/metastatic solid tumour or non-Hodgkins lymphoma. Patients with solid tumours may not have had more than 2 prior regimens for metastatic disease; patients with non-Hodgkins lymphoma must have, in the opinion of the investigator, failed all standard therapies.
Objective: To determine the safety, tolerability, toxicity profile and define a recommended phase II dose of AT7519M given as a one hour infusion twice weekly for two weeks every 21 days in patients with advanced incurable malignancy.
Participation: Limited to invited centres
Lay Description: The purpose of this study is to find out how much of the drug AT7519M can be given safely to patients with cancer when administered twice a week. This is done by starting at a dose already known to be safe in humans.
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| IND | I177 | 34 | 5 | 4 | 5 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| IND | I177 | 34 | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| IND | I177 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |